Form 4: Apogee Therapeutics Director Receives Stock Option Grant

Director Nimish P. Shah was granted options to purchase 7,657 shares of Apogee Therapeutics common stock.

Summary

• Director Nimish P. Shah received a grant of 7,657 stock options on June 9, 2026.
• The options have an exercise price of $85.00 per share.
• The options are scheduled to vest on the one-year anniversary of the grant date, June 9, 2027.
• The reporting person holds these options for the benefit of Venrock Management, LLC.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which carries a neutral sentiment.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• Dilutive impact of new option grants on existing shareholders.

Risks

• Market price volatility may affect the value of the options.
• Vesting is contingent upon continued service to the issuer.

Future Outlook

The options vest on June 9, 2027, subject to the director's continued service to the company.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure board alignment with corporate performance and long-term strategic goals.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with compensation practices at peer-group biotechnology firms.
• The one-year cliff vesting schedule is standard for director equity awards in the industry.

Related Party Transactions

• The reporting person holds the options for the benefit of Venrock Management, LLC, and is required to exercise them at the direction of the Management Company.

Stakeholder Impact

• Shareholders may experience minor dilution upon the eventual exercise of these options.

Next Steps

• Vesting of options on June 9, 2027.

Key Dates

Keywords

Apogee Therapeutics, APGE, Form 4, Insider Trading, Stock Options, Director Compensation